Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced results from a preclinical study of its novel oncology drug candidate, M402. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE